|
4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid Suppliers list
|
|
| | 4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid Basic information |
| Product Name: | 4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid | | Synonyms: | 4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid;HOOCCH2CH2O-PEG12-CH2CH2COOH/4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid;O,O'-Bis(2-carboxyethyl)dodecaethylene glycol | | CAS: | 2225903-66-0 | | MF: | C30H58O17 | | MW: | 690.77 | | EINECS: | | | Product Categories: | | | Mol File: | 2225903-66-0.mol |  |
| | 4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid Chemical Properties |
| Boiling point | 736.5±60.0 °C(Predicted) | | density | 1.159±0.06 g/cm3(Predicted) | | pka | 3.97±0.10(Predicted) |
| | 4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid Usage And Synthesis |
| Uses | Bis-PEG13-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1]. | | IC 50 | PEGs | | References | [1] An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562 DOI:10.1016/j.ebiom.2018.09.005 |
| | 4,7,10,13,16,19,22,25,28,31,34,37,40-Tridecaoxatritetracontanedioic acid Preparation Products And Raw materials |
|